Amprenavir

A potent HIV-1 protease inhibitor with IC50 of 80 nM, has mean IC50 of 12 nM against 6 HIV clinical isolates; shows synergistic effect with a variety of anti-HIV-1 agents and exhibits a unique cross resistance profile.HIV Infection Approved (In Vitro) :Amprenavir has an enzyme inhibition constant (Ki = 0.6 nM) that falls within the Ki range of the other protease inhibitors. Amprenavir's in vitro 50% inhibitory concentration (IC50) against wild-type clinical HIV isolates is 14.6 +/- 12.5 ng/mL (mean +/- SD) . Amprenavir had direct inhibitory effects on invasion of Huh-7 hepatocarcinoma cell lines, inhibiting MMP proteolytic activation . (In Vivo) :Amprenavir was able to promote regression of hepatocarcinoma growth in vivo by anti-angiogenetic and overall anti-tumor activities, independently by PI3K/AKT related pathways that at today is one of the more suggestive hypothesis to explain the anti-tumor effects of the different protease inhibitors . Amprenavir efficiently activated PXR and induced PXR target gene expression in vitro and in vivo. Short-term exposure to amprenavirsignificantly increased plasma total cholesterol and atherogenic low-density lipoprotein cholesterol levels in wild-type mice, but not in PXR-deficient mice . Amprenavir has been approved for adults and children; the recommended capsule doses are 1200 mg twice daily for adults and 20 mg/kg twice daily or 15 mg/kg 3 times daily for children < 13 years of age or adolescents < 50 kg .

161814-49-9

VX-478 | 141W94

Pharmacology & Drug Discovery

>98% (HPLC)

10 mM in DMSO

CC (C) CN (CC (C (CC1=CC=CC=C1) NC (=O) OC2CCOC2) O) S (=O) (=O) C3=CC=C (C=C3) N

C25H35N3O6S

505.6269

Storage temperature: -20°C. Stability: ≥ 2 years

For research use only.